Stock Analiz

Halozyme Therapeutics, Inc. (HALO) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Halozyme Therapeutics’s revenue went from $147M in fiscal 2016 to $1.4B in fiscal 2025, growth of about 28.5% a year.

Net income in fiscal 2025 was $317M, a net margin of 22.7%; the best year in this period was 2024 with $444M.

Over the twelve months to September 30, 2026, revenue was $1.8B and net income $485M.

Free cash flow was $645M in fiscal 2025 and positive in 7 of the 10 years shown.

The diluted share count fell 3% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $147M162017: $317M172018: $152M182019: $196M192020: $268M202021: $443M212022: $660M222023: $829M232024: $1.0B242025: $1.4B25$1.4B
Net income
2016: -$103M162017: $63M172018: -$80M182019: -$72M192020: $129M202021: $403M212022: $202M222023: $282M232024: $444M242025: $317M25$317M
Free cash flow
2016: -$54M162017: $133M172018: -$54M182019: -$89M192020: $53M202021: $298M212022: $235M222023: $373M232024: $468M242025: $645M25$645M
EPS (diluted)
2016: $-0.81162017: $0.45172018: $-0.56182019: $-0.50192020: $0.91202021: $2.74212022: $1.44222023: $2.10232024: $3.43242025: $2.5625$2.56

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.8B$1.4B$1.0B$829M$660M$443M$268M$196M$152M$317M$147M
Gross profit$1.5B$1.2B$856M$637M$521M$362M$224M$150M$142M$285M$113M
Operating income$674M$469M$551M$338M$268M$276M$144M-$68M-$69M$81M-$83M
Net income$485M$317M$444M$282M$202M$403M$129M-$72M-$80M$63M-$103M
EPS (diluted)$4.01$2.56$3.43$2.10$1.44$2.74$0.91$-0.50$-0.56$0.45$-0.81
R&D—$81M$79M$76M$67M$36M$34M$141M$150M$151M$151M
Revenue growth—+37.5%+22.4%+25.6%+48.9%+65.7%+36.5%+29.1%−52.0%+115.8%+8.6%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$898M$652M$479M$389M$240M$299M$55M-$85M-$50M$134M-$50M
Capital spending-$12M-$7M-$11M-$15M-$5M-$1M-$3M-$4M-$5M-$1M-$3M
Free cash flow$886M$645M$468M$373M$235M$298M$53M-$89M-$54M$133M-$54M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$400M$342M$250M$402M$200M$350M$150M$200M$0$0—
Stock-based pay$68M$52M$43M$37M$24M$21M$17M$35M$36M$31M$26M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$134M$116M$118M$363M$741M$368M$421M$58M$169M$67M
Debt—$2.2B$1.5B$1.5B$1.5B$879M$402M$409M$126M$202M$217M
Equity—$49M$364M$84M$170M$197M$151M$92M$249M$208M-$32M
Total assets—$2.5B$2.1B$1.7B$1.8B$1.1B$580M$566M$440M$520M$262M
Shares (diluted)123M124M129M134M141M147M141M144M144M139M128M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin82.3%83.6%84.3%76.8%78.9%81.6%83.8%76.8%93.3%90.2%77.4%
Operating margin37.4%33.6%54.3%40.7%40.5%62.2%53.9%-34.5%-45.6%25.6%-56.7%
Net margin26.9%22.7%43.7%34.0%30.6%90.8%48.2%-36.9%-52.9%19.9%-70.2%
FCF margin49.1%46.2%46.1%45.0%35.6%67.2%19.8%-45.6%-35.7%41.9%-36.5%
ROIC—14.3%23.1%16.9%12.7%20.2%26.0%-13.5%-14.6%15.6%-35.7%
ROE—649.2%122.1%336.0%119.0%204.5%85.5%-78.7%-32.3%30.2%317.2%

Frequently asked questions

What is Halozyme Therapeutics’s annual revenue?

$1.4B in fiscal 2025 and $1.8B over the twelve months to September 30, 2026.

How much profit does Halozyme Therapeutics make?

Net income was $317M in fiscal 2025 (net margin 22.7%).

Is Halozyme Therapeutics’s revenue growing?

Yes: revenue rose 37.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.